Harvard Bioscience (HBIO) vs Seer (SEER)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Harvard Bioscience (HBIO) has outperformed Seer (SEER) over the past year, gaining 84.8% versus a loss of 3.6%. Over five years, HBIO leads with a -88.1% price change compared with -93.3% for SEER. Seer is the larger company by market cap ($120.2 million vs $37.0 million), about 3.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HBIO | SEER |
|---|---|---|
| Share price | $8.13 | $2.17 |
| Market cap | $37.01M | $120.16M |
| 1-day change | -4.35% | -1.81% |
| YTD return | +21.34% | +18.58% |
| 1-year return | +84.77% | -3.56% |
| 5-year return | -88.11% | -93.30% |
| Forward P/E | 12.60 | — |
| EPS (TTM) | $-2.31 | $-1.22 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $9.40 | $2.41 |
| 52-week low | $3.80 | $1.55 |
| Distance from 52-week high | -13.51% | -9.96% |
| Analyst consensus | none | none |
| Avg. price target upside | -7.75% | +84.33% |
| Average volume | 17.87K | 481.54K |
| Shares outstanding | 4.55M | 55.37M |
| Employees | 316 | 124 |
| Sector | Healthcare | Industrials |
| Industry | Medical Instruments & Supplies | Biotechnology: Laboratory Analytical Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Seer is about 3.2 times larger than Harvard Bioscience by market value ($120.16M vs $37.01M).
- HBIO has outperformed SEER by 88.3 percentage points over the past year.
- The two companies sit in different sectors: Harvard Bioscience in Healthcare and Seer in Industrials.
About Harvard Bioscience
HBIO stock →Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the Americas, Europe, the Middle East, Africa, Asia, and internationally.
Healthcare · Medical Instruments & Supplies · 316 employees
About Seer
SEER stock →Seer, Inc., a life sciences company, develops and commercializes products to decode the biology of the proteome to improve human health in the United States, China, Australia, Europe, Israel, Japan, and South Africa. The company offers Proteograph Product Suite, an integrated solution, which includes proprietary engineered nanoparticles, consumables, automation instrumentation, and data analysis software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only.
Industrials · Biotechnology: Laboratory Analytical Instruments · 124 employees
HBIO vs SEER FAQ
Which is bigger, Harvard Bioscience or Seer?
Seer (SEER) is larger, with a market capitalization of $120.16M compared with $37.01M for Harvard Bioscience (HBIO).
Which stock has performed better over the past year, HBIO or SEER?
HBIO returned +84.77% over the past 12 months, compared with -3.56% for SEER (price return, excluding dividends). Past performance does not predict future results.
Are Harvard Bioscience and Seer in the same industry?
No. Harvard Bioscience is in the Healthcare sector, while Seer is in Industrials.